Abstract 15991: Lipoprotein-associated Phospholipase A2 Levels Are Associated With Vascular Function in Patients With Coronary Artery Disease
Introduction: Lipoprotein-associated Phospholipase A2 (Lp-PLA2), has a powerful inflammatory and atherogenic action in the vascular wall and is an independent marker of poor prognosis in coronary artery disease (CAD). Endothelial function and arterial stiffness are key players in the pathophysiology of atherosclerotic disease and measurement of endothelial function and arterial stiffness are well validated as a strong prognostic markers.
Hypothesis: We hypothesized that levels of Lp-PLA2 are associated with endothelial function and arterial stiffness in patients with stable CAD.
Methods: We enrolled 330 consecutive patients with stable CAD. Endothelial function was evaluated by flow-mediated dilation (FMD) in the brachial artery. Augmentation index (AIx) of the central aortic pressure was estimated non-invasively as a measure of arterial stiffness. Serum levels of Lp-PLA2 were measured with ELISA. Several demographic and clinical characteristics were also collected.
Results: The mean age of the participants was 62±11 years and 60% were males. In the study population the median values of Lp-PLA2 levels with 1st and 3rd quartile was 123 (92-151)μg/L. There was no difference between subjects with Lp-PLA2 levels above and below 123μg/L (median value) in age(62±11 years vs. 63±10 years, p=0.27), male gender (63% vs 58%, p=0.23), smoking habits (25% vs. 22%, p=0.51), body mass index (28.36±3.50Kgr/m2 vs. 29.72±2.49Kgr/m2, p=0.43), creatinine levels (0.96±0.22 mg/dl vs. 1.05±0.76mg/dl, p=0.20) and in the presence of hypertension (83% vs. 79%, p=0.44). Importantly, subjects with Lp-PLA2 levels above 123μg/L compare to subjects with lower values of Lp-PLA2 had significantly impaired values of FMD (4.61±2.22% vs. 5.11±2.47%, p=0.04) and AIx (24.89±8.97% vs. 22.71±9.36%, p=0.03).
Conclusions: Elevated Lp-PLA2 concentration is related with endothelial dysfunction and arterial stiffness in patients with stable CAD. These findings highlight the significant role of Lp-PlA2 in the progression of atherosclerosis and the potential need to further investigate if pharmaceutical reduction of Lp-PLA2 levels would improve vascular markers of atherosclerosis and thus, would beneficially affect prognosis in patients with CAD.
Author Disclosures: G. Siasos: None. E. Oikonomou: None. M. Zaromitidou: None. K. Mourouzis: None. A. Miliou: None. G. Georgiopoulos: None. A. Antonopoulos: None. G. Papamikroulis: None. G. Vogiatzi: None. S. Tsalamandris: None. M. Vavuranakis: None. D. Tousoulis: None.
- © 2016 by American Heart Association, Inc.